[Other]Nivolumab Plus Ipilimumab for Soft Tissue Sarcoma: A Single Institution Retrospective Review

Post time 1 hour(s) ago

Abstract

Aim: To analyze the efficacy of checkpoint inhibitors in soft tissue sarcoma. Materials & methods: We retrospectively reviewed patients with advanced soft tissue sarcoma treated with ipilimumab and nivolumab. All patients who received at least one cycle were included. Results: One patient had a complete response and five had a partial response, for an objective response rate of 15%. Clinical benefit rate was 34% with a median duration of 12.0 months (range: 4.5 to 28.9+ months [mo]). Median overall survival was 12.0 months (95% CI: 4.5–23.7+ mo). Median progression-free survival was 2.7 months (95% CI: 2.3–4.5+ mo) by Response Evaluation Criteria in Solid Tumors 1.1 and 2.9 months (2.5–6.0+ mo) by immune-related Response Evaluation Criteria in Solid Tumors. Adverse events of any grade were seen in 58% of patients, the most common being fatigue (21%) and cough (10%), 5% of patients experienced a grade 3 adverse event (AE) (hyperglycemia) or grade 4 AE (myocarditis). Conclusion: Ipilimumab/nivolumab combination showed efficacy and was well tolerated in advanced soft tissue sarcoma.

[Other] [Other]Nivolumab Plus Ipilimumab for Soft Tissue Sarcoma: A Single Institution Retrospective Review

Reply

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Other] [Other]Nivolumab Plus Ipilimumab for Soft Tissue Sarcoma: A Single Institution Retrospective Review Copy

Reply

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Other] [Other]Nivolumab Plus Ipilimumab for Soft Tissue Sarcoma: A Single Institution Retrospective Review